Grants and Contributions:
Title:
Predictive Diagnostic for Cancer
Agreement Number:
906588
Agreement Value:
$45,555.00
Agreement Date:
May 1, 2018 - Mar 31, 2019
Description:
Estrogen Receptor (ER) Positive breast cancer is the most common type and can be effectively treated with endocrine therapy. However, the major challenge is the endocrine therapy resistance and breast cancer recurrence in 50% of the patients. VastCo is developing a novel predictive test that could be combined with the receptor status test for the prediction of treatment response to endocrine therapy. This test would help Clinical Oncologists to design treatment regimen for better clinical outcome.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Winnipeg, Manitoba, CA R3Y 0A2
Reference Number:
172-2018-2019-Q1-906588
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
810234633
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 2 time(s). The end date of this agreements has been modified by 16 days. The total amended value is -4,445 dollars.
Amendment Date
Mar 13, 2019
Recipient's Legal Name:
Vastcon Inc.
Federal Riding Name:
Winnipeg South
Federal Riding Number:
46013
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
33911
Amendments: